EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials

Grace Lu, Tyler Cepica, Catherine Barbey, Ilimbek Beketaev, Denesh Chitkara, Anthony P Fernandez, Shimon Korish, Joseph F Merola, Jill A Lindstrom, Nikolay P Nikolov, Hoang Nguyen, Christopher T Richardson und 4 weitere

Nature Reviews Rheumatology · 2026

DOI: 10.1038/s41584-025-01351-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Reviews Rheumatology, 2026. Verfasst von Grace Lu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Clinical Trials as Topic, Severity of Illness Index, Outcome Assessment, Health Care. Die Arbeit nennt 76 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous lupus erythematosus (CLE) is an autoimmune skin condition associated with a considerable treatment burden and diminished quality of life. The absence of a consensus outcome measure to evaluate therapeutic response has posed a challenge to CLE drug development. The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) was developed in response to this need, incorporating morphological components including erythema, scale, dyspigmentation and scarring, to reflect disease activity and damage. Numerous studies have demonstrated the utility of CLASI in capturing relevant aspects of disease from clinician- and patient-based perspectives; however, no regulatory precedent for use of clinical trial data employing CLASI to evaluate treatment response in CLE exists. Thus, the Lupus Accelerating Breakthroughs Consortium commissioned a working group of members from industry, academia, the US Food and Drug Administration (FDA) and CLE patient advocates to address the potential knowledge gaps with CLASI through evidence-based research. Upon reviewing and submitting these data to the FDA, the working group reached alignment that CLASI is a suitable outcome measure for CLE clinical trials, enabling a clearer regulatory path for clinical drug development. The group recognizes the need for additional information to assess what degree of change in CLASI captures clinically meaningful improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, CutaneousClinical Trials as TopicSeverity of Illness IndexOutcome Assessment, Health CareHumansUnited StatesUnited States Food and Drug AdministrationTreatment OutcomeQuality of Life

Autor:innen und Institutionen

  • Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Biogen, Baar, Switzerland.
  • AstraZeneca, Durham, NC, USA.
  • EMD Serono, Boston, MA, USA.
  • Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, OH, USA.
  • Bristol Meyers Squibb, Princeton, NJ, USA.

Zitieren

APA

Lu, G., Cepica, T., Barbey, C., Beketaev, I., Chitkara, D., Fernandez, A. P., Korish, S., Merola, J. F., Lindstrom, J. A., Nikolov, N. P., Nguyen, H., Richardson, C. T., Staeva, T. P., Werth, V. P., Chong, B. F., & Lupus Accelerating Breakthroughs Consortium CLASI Working Group (2026). Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-025-01351-5

Vancouver

Lu G, Cepica T, Barbey C, Beketaev I, Chitkara D, Fernandez AP, et al. Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials. Nature Reviews Rheumatology. 2026. doi:10.1038/s41584-025-01351-5

BibTeX
@article{Lu2026,
  author = {Lu, Grace and Cepica, Tyler and Barbey, Catherine and Beketaev, Ilimbek and Chitkara, Denesh and Fernandez, Anthony P and Korish, Shimon and Merola, Joseph F and Lindstrom, Jill A and Nikolov, Nikolay P and Nguyen, Hoang and Richardson, Christopher T and Staeva, Teodora P and Werth, Victoria P and Chong, Benjamin F and Lupus Accelerating Breakthroughs Consortium CLASI Working Group, Lupus Accelerating Breakthroughs Consortium CLASI Working Group},
  title = {Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials},
  journal = {Nature Reviews Rheumatology},
  year = {2026},
  doi = {10.1038/s41584-025-01351-5}
}
Kostenlos starten →